The Agenda

Agenda – What’s on when

7:00 – 7:55

Registration and Check-in          Light Breakfast Served

7:55 – 8:00

Genomic Workshop – Welcome and Learning Objectives

Scientific Program Committee

Maher Albitar, MD, Genomic Testing Cooperative

Gustavo Rivero, MD, Tampa General Hospital Cancer Institute

Anne Renteria MD, New York University

David Swoboda, MD, Tampa General Hospital Cancer Institute

8:00 – 9:00

Keynotes

Session Chair Introduction

David Swoboda, MD, Tampa General Hospital Cancer Institute

8:00-8:15

Evolving Concepts in Myeloid Neoplasm Sequencing

Maher Albitar, MD, Genomic Testing Cooperative

8:15-8:30

Myeloid and Non-Myeloid Clonal Hematopoiesis

Maher Albitar, MD, Genomic Testing Cooperative

David Swoboda, MD, Tampa General Hospital Cancer Institute

8:30-8:50

Myeloid Germline Predisposition

Maher Albitar, MD, Genomic Testing Cooperative

Lacey Williams, MD, University of North Carolina School of Medicine

9:00 – 10:00

Session 1: Evolution into Myeloid Leukemogenesis

Session Chair Introduction

Gustavo Rivero, MD, Tampa Genral Hospital Cancer Institute

9:00-9:20

MDS to AML

Maher Albitar, MD, Genomic Testing Cooperative

Gustavo Rivero, MD, Tampa Genral Hospital Cancer Institute

9:20-9:50

AML-Bioinformatic Pipeline Applicability – 2 Tumor Board Cases

Maher Albitar, MD, Genomic Testing Cooperative 

David Swoboda, MD, TGH Cancer Institute 

9:50-10:00

Q & A

Maher Albitar, MD, Genomic Testing Cooperative 

David Swoboda, MD, TGH Cancer Institute 

10:00-10:15

Coffee Break

10:15-11:30

Session 2: Myelodysplastic Syndrome

Session Chair Introduction

David Sallman, MD, Moffitt Cancer Center, University of South Florida 

10:15-10:40

Inherited Bone Marrow Failure – Case Tumor Board

Maher Albitar, MD, Genomic Testing Cooperative

David Sallman, MD, Moffitt Cancer Center, University of South Florida 

10:40-11:00

Low-Risk MDS

Maher Albitar, MD, Genomic Testing Cooperative

Gustavo Rivero, MD, Tampa General Hospital Cancer Institute

11:00-11:30

High-Risk MDS

Maher Albitar, MD, Genomic Testing Cooperative

David Swoboda, MD, Tampa General Hospital Cancer Institute

11:30-11:55

Lunch is being combined with the combined with the product theater below 

11:55-12:40

Product Theater – The Actionable MDS Genome-Telomerase Inhibitors

13:00 – 14:00

Session 3:  Myeloproliferative Neoplasm

Session Chair Introduction

Iberia Romina Sosa, MD, PhD, Fox Chase Cancer Center, Temple Health

13:00-13:30

MPN Diagnosis

Maher Albitar, MD, Genomic Testing Cooperative

Iberia Romina Sosa, MD, PhD, Fox Chase Cancer Center, Temple Health

13:30-14:00

MPN Transformation to Blastic Phase

Maher Albitar, MD, Genomic Testing Cooperative

Iberia Romina Sosa, MD, PhD, Fox Chase Cancer Center, Temple Health

14:00-14:10

Coffee Break

14:10-15:10

Session 4: Lymphomas

Session Chair Introduction

Eduardo Sotomayor, MD, Tampa General Hospital Cancer Center Institute

14:10-14:40

Diffuse Large B-Cell Lymphoma

Maher Albitar, MD, Genomic Testing Cooperative

Alan Kerr, II, MD, PhD, Tampa General Hospital Cancer Institute

14:40-15:00

Lymphoma MRD

Maher Albitar, MD, Genomic Testing Cooperative

Nikesh Shah, MD, Tampa General Hospital Cancer Center Institute

15:00-16:00

Session 5: Multiple Myeloma

Session Chair Introduction

Ivan Borrello, MD, Tampa General Hospital Cancer Institute

15:00-15:20

The Myeloma Genome

Ivan Borrello, MD, Tampa General Hospital Cancer Institute

15:20-15:40

Myeloma Tumor Board

Maher Albitar, MD, Genomic Testing Cooperative

Ivan Borrello, MD, Tampa General Hospital Cancer Institute

15:40-16:00

Myeloma MRD

Saturday – May 17, 2025

7:00-7:55

Registration and Check-in          Light Breakfast         

7:55-8:00

Hematologic Malignancies Symposium – Welcome and Learning Objectives

Scientific Program Committee

Gustavo Rivero, MD, Tampa General Hospital Cancer Institute

Anne Renteria, MD, New York University

David Swoboda, MD, Tampa General Hospital Cancer Institute

Maher Albitar, MD, Genomic Testing Cooperative

8:00 – 8:20

Featured Lecture

Session Chair Introduction

Gustavo Rivero, MD, Tampa General Hospital Cancer Institute, Tampa, FL 

8:00-8:20

Manipulating the Leukemia Stem Cell Microenvironment

Tiphaine Martin, MEg, PhD, Icahn School of Medicine at Mount Sinai

8:20-9:20

Session 1: Implementing a Clonal Hematopoiesis Clinic

Session Chair Introduction

Gustavo Rivero, MD, Tampa General Hospital Cancer Institute

8:20-8:40

What Important Primary Aims Should be Considered for a CHIP Clinic?

Ludovica Marando, PhD , Mayo Clinic

8:40-9:00

UK BioBanking Insights: CHIP to Hemopoietic Malignancy Conversion

Pedro Quiros, PhD, Wellcome- MRC Cambridge Stem Cell Institute (UK)

9:00-9:20

How to Integrate CHIP and Atherosclerosis Risk

9:20-10:20

Session 2: Myelodysplastic Syndrome

Session Chair Introduction

9:20-9:40

ICC vs WHO Classification – Pros and Cons

Stephen D. Nimer, MD, Sylvester Comprehensive Cancer Center 

9:40-10:00

Drug Development in MDS

10:00-10:20

Novel Trials in MDS

David Sallman, MD, Moffitt Cancer Center, University of South Florida 

10:30-11:30

Session 3: Racial Disparity and Myeloid Malignancies

Session Chair Introduction

Gustavo Rivero, MD, Tampa General Hospital Cancer Institute

10:30-10:50

Molecular Basis of Myeloid Malignancies Racial Disparity

Ann-Kathrin Eisfeld, MD, Ohio State University

10:50-11:10

Social and Genomics Interaction in Myeloid Malignancies

Lacey Williams, MD, University of North Carolina

11:10-11:30

Q & A

11:30-11:45

Lunch – This is being combined with the TGH Cancer Institute Sponsored Session Below 11:45-13:00

11:45 – 13:00

Tampa General Hospital Cancer Institute Sponsored Session:

HTLV from Discovery to Genomics

Session Co-Chairs

Eduardo Sotomayor, MD, Tampa General Hospital Cancer Institute

Gustavo Rivero, MD, Tampa General Hospital Cancer Institute

11:45-12:10

History of HTLV1 Discovery

Robert C. Gallo, MD, Tampa General Hospital Cancer Institute

12:10-12:35

Genomics of HTLV1: Unveiling Novel Targets

Yutaka Tagaya, MD, Tampa General Hospital Cancer Institute

12:35-13:00

HTLV Induced Adult T-Cell Leukemia/Lymphoma

Maher Albitar, MD, Genomic Testing Cooperative

Alan Kerr, II, MD, PhD, Tampa General Hospital Cancer Institute

13:00-15:25

Session 4: AML Highlights – What Physicians Should Know

Session Chair Introduction

David Swoboda, MD, Tampa General Hospital Cancer Institute

13:00-13:25

The AML Epigenome- Recent Advances

Jonathan Licht, MD, University of Florida Health Cancer Center

13:25-13:50

Advances in AML MRD Testing

Manja Meggendorfer, PhD, Munich Leukemia Laboratory

13:50-14:10

How I Manage FLT3 Mutated AML

David Swoboda, MD, Tampa General Hospital Cancer Institute

14:10-14:30

How I Manage MLL Rearranged AML

Jeffrey Lancet, MD, Lee Moffitt Cancer Center, Tampa

14:30-14:50

Advances in AML Immunology

Sergio Rutella, MD, Nottingham University, United Kingdom

14:50-15:15

Coffee Break

15:15-16:35

Session 5: Cellular Therapy

Session Chair Introduction

Anne Renteria, MD, New York University

15:15-14:35

Advances in GVHD Prophylaxis

Mohammad Maher Abdul Hay, MD, NYU Grossman School of Medicine

15:35-15:55

HLA Matching in Allogeneic Cellular Transplantation

Olga Timofeeva, PhD, UCLA

15:55-16:15

Advances in AML CAR T-cell Therapies

Jingmei Hsu, MD, New York University

16:15-16:35

Fitness and Supportive Care in Malignant Hematology for Allo-HCT

Anne Renteria, MD, New York University

16:35-16:45

REGISTRATION
OPEN

SPONSOR

Interested in sponsoring the event? Email Nigel Russell by using the link below!

Tampa General Hospital